Log in

NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price, Forecast & News

$89.73
+5.05 (+5.96 %)
(As of 02/27/2020 03:07 AM ET)
Today's Range
$85.87
Now: $89.73
$92.00
50-Day Range
$84.68
MA: $99.26
$117.54
52-Week Range
$56.76
Now: $89.73
$125.00
Volume633,734 shs
Average Volume548,776 shs
Market Capitalization$2.94 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.74
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$179.80 million
Book Value$0.64 per share

Profitability

Net Income$-309,240,000.00
Net Margins-143.09%

Miscellaneous

Employees483
Market Cap$2.94 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter.


Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) released its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported ($2.99) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.52) by $0.47. The biopharmaceutical company earned $71.50 million during the quarter, compared to the consensus estimate of $68.19 million. Intercept Pharmaceuticals had a negative net margin of 143.09% and a negative return on equity of 495.47%. The firm's revenue was up 34.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.97) earnings per share. View Intercept Pharmaceuticals' Earnings History.

When is Intercept Pharmaceuticals' next earnings date?

Intercept Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Intercept Pharmaceuticals.

What price target have analysts set for ICPT?

18 Wall Street analysts have issued 12-month price objectives for Intercept Pharmaceuticals' stock. Their forecasts range from $102.00 to $257.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $154.07 in the next year. This suggests a possible upside of 71.7% from the stock's current price. View Analyst Price Targets for Intercept Pharmaceuticals.

What is the consensus analysts' recommendation for Intercept Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 3 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intercept Pharmaceuticals.

What are Wall Street analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Intercept’s lead drug Ocaliva’s performance has been strong in the year so far. Management’s efforts to increase awareness about the label update of the drug in 2018 and expand sales force across the United States, thereafter, are yielding results. Solid growth in patient enrollment is likely to drive the company’s performance. Meanwhile, Intercept is working to expand the drug’s label in the promising NASH space. While the failure of Gilead’s late-stage study on selonsertib in patients suffering from compensated cirrhosis due to NASH puts Intercept ahead in the race, additional results from the REGENERATE study in NASH were mixed and did not impress investors. Nevertheless, a potential approval in this indication will significantly boost growth. However, shares have underperformed the industry in the year so far." (10/14/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis." (8/12/2019)

Has Intercept Pharmaceuticals been receiving favorable news coverage?

News coverage about ICPT stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Intercept Pharmaceuticals earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Intercept Pharmaceuticals.

Are investors shorting Intercept Pharmaceuticals?

Intercept Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,910,000 shares, an increase of 8.1% from the January 15th total of 4,540,000 shares. Based on an average daily trading volume, of 684,600 shares, the days-to-cover ratio is presently 7.2 days. Currently, 19.5% of the company's stock are sold short. View Intercept Pharmaceuticals' Current Options Chain.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), Netflix (NFLX), Alibaba Group (BABA), NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Micron Technology (MU), Biogen (biib) and Celgene (CELG).

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:
  • Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 51)
  • Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 49)
  • Mr. Jerome B. Durso, Chief Operating Officer (Age 51)
  • Mr. Ryan T. Sullivan, Gen. Counsel & Sec. (Age 43)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance (Age 57)

Who are Intercept Pharmaceuticals' major shareholders?

Intercept Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.38%), Geode Capital Management LLC (1.10%), Pinnacle Associates Ltd. (0.53%), Jennison Associates LLC (0.52%), Charles Schwab Investment Management Inc. (0.50%) and Goldman Sachs Group Inc. (0.47%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Francesco Micheli, Gail Cawkwell, Jason Campagna, Keith Michael Gottesdiener, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, SPA Genextra and Srinivas Akkaraju. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Which major investors are selling Intercept Pharmaceuticals stock?

ICPT stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., First Trust Advisors LP, Peregrine Capital Management LLC, Rafferty Asset Management LLC, Spark Investment Management LLC, Schonfeld Strategic Advisors LLC, Man Group plc and Chicago Equity Partners LLC. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, David A Ford, David Shapiro, Gail Cawkwell, Jason Campagna, Lisa Bright, Mark Pruzanski, Paolo Fundaro and Ryan T Sullivan. View Insider Buying and Selling for Intercept Pharmaceuticals.

Which major investors are buying Intercept Pharmaceuticals stock?

ICPT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Pictet Asset Management Ltd., California Public Employees Retirement System, Cubist Systematic Strategies LLC, Geode Capital Management LLC, W.E. Donoghue & Co. LLC, Bank of New York Mellon Corp and EAM Investors LLC. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener, Luca Benatti, Mark Pruzanski and Srinivas Akkaraju. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $89.73.

How big of a company is Intercept Pharmaceuticals?

Intercept Pharmaceuticals has a market capitalization of $2.94 billion and generates $179.80 million in revenue each year. The biopharmaceutical company earns $-309,240,000.00 in net income (profit) each year or ($10.86) on an earnings per share basis. Intercept Pharmaceuticals employs 483 workers across the globe.View Additional Information About Intercept Pharmaceuticals.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is http://www.interceptpharma.com/.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]


MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  994 (Vote Outperform)
Underperform Votes:  606 (Vote Underperform)
Total Votes:  1,600
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel